Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003466 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00003466 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 100 participants.
The verdict
NCT00003466, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with progressive low-grade glioma.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1998-03 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003466
The ClinicalTrials.gov registry entry for NCT00003466 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00003466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003466 about?
NCT00003466 is a clinical study titled "Temozolomide in Treating Patients With Progressive Low-Grade Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with progressive low-grade glioma.
What is the current status of trial NCT00003466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1998-03. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00003466?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00003466?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.